ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Sarcoma

Sarcoma

A case study found that a patient with an inflammatory myofibroblastic tumor and a chromoplectic TPM3-ALK rearrangement that may be involved in tumorigenesis had a strong response to the ALK inhibitor ceritinib.

The use of a metronomic chemotherapy approach did not improve over standard chemotherapy in patients with high-grade, non-metastatic, operable osteosarcoma of the extremities.

A phase II trial found that the multikinase inhibitor regorafenib has clinical activity and offers improved progression-free survival in certain types of advanced soft-tissue sarcoma.

The FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of soft-tissue sarcomas that is not amenable to curative treatment with radiotherapy or with surgery and with a histologic subtype treatable with anthracycline-containing regimens.

A trial of five rare sarcoma subtypes found that though dasatinib failed to achieve progression-free survival goals, more than half of patients with certain subtypes did have reasonably good survival outcomes.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent case report of a 1.7-million-year-old osteosarcoma found in an extinct human lineage.

The addition of palifosfamide to doxorubicin failed to improve survival in a phase III trial of patients with metastatic soft-tissue sarcoma.

Pages

Subscribe to Sarcoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.